Actively Recruiting

Phase 4
Age: 18Years +
All Genders
NCT06964464

Comparative Effectiveness of Carvedilol Versus Metoprolol Succinate in Heart Failure Patients With an Implantable Cardioverter Defibrillator

Led by University of Rochester · Updated on 2025-09-18

2000

Participants Needed

13

Research Sites

306 weeks

Total Duration

On this page

Sponsors

U

University of Rochester

Lead Sponsor

P

Patient-Centered Outcomes Research Institute

Collaborating Sponsor

AI-Summary

What this Trial Is About

This prospective, multicenter, open-label, randomized comparative effectiveness trial, titled CARVTOP-ICD, evaluates the impact of carvedilol versus metoprolol succinate in patients with heart failure with reduced ejection fraction (HFrEF) and an implantable cardioverter defibrillator (ICD). The study will enroll 2,000 participants across 100 U.S. sites and includes an 18-month feasibility phase with 100 participants from 15 sites. Eligible participants must be currently treated with metoprolol succinate and willing to switch to carvedilol, with randomization in a 1:1 ratio. Participants will be followed for up to 3 years, with regular assessments including ICD interrogations, medication adherence, healthcare utilization, and quality of life surveys. The primary endpoint is the first occurrence of any ICD therapy (appropriate or inappropriate), cardiovascular (CV) hospitalization, or CV death. Secondary endpoints include ICD shock burden, healthcare utilization, and patient-reported quality of life. The trial aims to provide high-quality comparative data to address clinical equipoise surrounding the two commonly used beta-blockers in HFrEF management.

CONDITIONS

Official Title

Comparative Effectiveness of Carvedilol Versus Metoprolol Succinate in Heart Failure Patients With an Implantable Cardioverter Defibrillator

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 18 years or older
  • Implantable cardioverter defibrillator (ICD) implanted for primary prevention of heart failure with reduced ejection fraction (HFrEF) of ischemic or non-ischemic cause with remote monitoring capability
  • Currently treated with metoprolol succinate and willing to switch to carvedilol
  • Left ventricular ejection fraction (LVEF) less than 50% in the past 12 months before consent
Not Eligible

You will not qualify if you...

  • Unwilling or unable to follow the study protocol
  • Treated with any beta-blocker other than metoprolol succinate or not treated with any beta-blocker
  • Known intolerance or contraindication to carvedilol
  • Systolic blood pressure less than 100 mmHg
  • Currently enrolled in another clinical trial
  • Unable or unwilling to provide consent

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 13 locations

1

HonorHealth

Scottsdale, Arizona, United States, 85258

Actively Recruiting

2

AdventHealth Redmond

Rome, Georgia, United States, 30165

Actively Recruiting

3

AdventHealth Shawnee Mission

Shawnee Mission, Kansas, United States, 66204

Actively Recruiting

4

Henry Ford Health System

Detroit, Michigan, United States, 48202

Actively Recruiting

5

University of Mossouri

Columbia, Missouri, United States, 65212

Actively Recruiting

6

Creighton University Medical Center

Omaha, Nebraska, United States, 68124

Actively Recruiting

7

Suny Downstate

Brooklyn, New York, United States, 11203

Actively Recruiting

8

New York-Presbyterian Brooklyn Methodist Hospital

Brooklyn, New York, United States, 11215

Actively Recruiting

9

University of Rochester Medical Center

Rochester, New York, United States, 14642

Actively Recruiting

10

CHRISTUS Trinity Mother Frances Health System

Tyler, Texas, United States, 75701

Actively Recruiting

11

Health University of Utah

Salt Lake City, Utah, United States, 84112

Actively Recruiting

12

Virginia Commonwealth University

Richmond, Virginia, United States, 23298

Actively Recruiting

13

University of Wisconsin Hospital and Clinics

Madison, Wisconsin, United States, 53792

Actively Recruiting

Loading map...

Research Team

M

Mehmet Aktas, M.D.

CONTACT

N

Nicole Guerrero, MBA

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here